¶ Eicosapentaenoic Acid
¶ Definition
A 20-carbon omega-3 polyunsaturated fatty acid (20:5n-3) with five double bonds, obtained primarily from marine sources (fatty fish, algae) or inefficiently synthesized from plant-based alpha-linolenic acid. EPA serves as the precursor for E-series resolvins and 3-series prostaglandins, competes with arachidonic acid for COX and LOX enzymes, and modulates inflammatory gene transcription via PPAR and NF-κB pathways.
¶ Picture It
Think of your cell membranes as a crowded nightclub with limited VIP spots. Arachidonic acid (AA) is the troublemaker friend who always starts fights—when the bouncer (PLA2) lets AA into the main floor, the enzymatic DJs (COX-2, 5-LOX) remix AA into inflammatory party tracks: 2-series prostaglandins and 4-series leukotrienes. The party gets wild, immune cells show up, inflammation escalates.
Now EPA shows up—same VIP access (it's also a 20-carbon fatty acid), but it's the chill friend who de-escalates. When PLA2 releases EPA instead of AA, the same DJs now produce mellow 3-series prostaglandins and 5-series leukotrienes—much less inflammatory. Even better, EPA goes to a different room where specialized enzymes (15-LOX, aspirin-acetylated COX-2) turn EPA into resolvins—molecular peacekeepers (RvE1, RvE2, RvE3) that actively shut down the party, clear out the debris, and restore order. The more EPA you have in the membrane (from diet or supplements), the less room there is for AA, and the more resolution mediators you make when inflammation needs to end.
¶ Mechanism
Incorporation and Competition:
- Dietary EPA (from fish oil, algae) or endogenous EPA (from hepatic elongation/desaturation of ALA via delta-6 desaturase → delta-5 desaturase, ~5-10% conversion efficiency in humans) is absorbed in the small intestine and transported via chylomicrons
- EPA incorporates into membrane phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol) at the sn-2 position, displacing arachidonic acid
- This changes membrane fluidity (increases flexibility), alters lipid raft composition, and modifies receptor clustering and signaling platform assembly
Enzymatic Metabolism:
When PLA2 (phospholipase A2) releases EPA from the membrane:
-
COX pathway: EPA + COX-1/COX-2 → 3-series prostaglandins (PGE3, PGI3)
- PGE3 is 10-fold less potent than PGE2 at inducing fever, pain, and vascular permeability
- PGI3 (prostacyclin from EPA) is equipotent to PGI2 as a vasodilator but less pro-inflammatory
-
LOX pathway: EPA + 5-LOX → 5-series leukotrienes (LTB5)
- LTB5 is 10-100× less chemotactic for neutrophils than LTB4 (from AA)
- This reduces neutrophil recruitment and activation
-
Resolvin E-series biosynthesis:
- EPA + aspirin-acetylated COX-2 → 18R-HEPE (18R-hydroxy-eicosapentaenoic acid)
- 18R-HEPE + 5-LOX → RvE1 (resolvin E1)
- EPA + cytochrome P450 → 18S-HEPE → RvE2
- EPA + 15-LOX → RvE3
- Resolvins bind to specific GPCRs: RvE1 → ChemR23/ERV1 and BLT1 (blocks LTB4), RvE2 → BLT1, RvE3 → multiple targets
Transcriptional Regulation:
- EPA activates PPAR-α and PPAR-γ (peroxisome proliferator-activated receptors)
- PPAR activation → upregulates fatty acid oxidation genes (CPT1A, ACOX1), downregulates lipogenic genes (SREBP-1c, FAS)
- EPA inhibits NF-κB translocation by preventing IκB degradation → reduced transcription of IL-6, TNF-α, COX-2, iNOS
- EPA modulates histone deacetylase activity and DNA methylation patterns (epigenetic anti-inflammatory effects)
Resolution Mechanisms via Resolvins:
- RvE1 → ChemR23 → cAMP ↑ → PKA activation → CREB phosphorylation → IL-10 transcription (macrophage phenotype shift M1→M2)
- RvE1 → BLT1 antagonism (blocks LTB4-driven neutrophil chemotaxis)
- RvE2/RvE3 → enhanced macrophage phagocytosis of apoptotic neutrophils (efferocytosis)
- Resolvins reduce NETosis (neutrophil extracellular trap formation), preventing chronic inflammation amplification
¶ Clinical Significance
cPNI Protocol Application:
In cPNI practice, EPA supplementation (combined with DHA as 1 gram/day additional to base formulations like cPNI10) specifically targets hypothalamic neuroinflammation—a central node in metabolic disease, chronic stress axis dysregulation, and obesity. The hypothalamus is uniquely vulnerable because it lacks a complete blood-brain barrier at circumventricular organs (median eminence, OVLT), allowing circulating fatty acids and inflammatory mediators direct access.
Selfish Brain Context:
EPA interrupts the vicious cycle where hypothalamic inflammation → leptin resistance → insulin resistance → further inflammation. By providing EPA, you shift the brain's local lipid mediator profile from pro-inflammatory (AA-derived) to pro-resolving (EPA-derived), restoring hypothalamic sensitivity to metabolic hormones. This aligns with the selfish brain theory: a neuroinflamed hypothalamus cannot accurately regulate peripheral metabolism—it becomes "deaf" to satiety signals and overdrives cortisol/insulin to secure glucose for itself.
Evolutionary Mismatch:
Modern diets have omega-6:omega-3 ratios of 15-20:1 (versus ancestral ~1-4:1). This AA excess saturates membranes, priming for exaggerated inflammatory responses. EPA supplementation is a mismatch correction—restoring membrane fatty acid ratios closer to evolutionary norms, where marine and wild game consumption provided abundant omega-3s.
Clinical Thresholds and Testing:
- Omega-3 Index (RBC membrane EPA+DHA %): target >8% for cardiovascular/neurological protection; <4% is high-risk
- AA/EPA ratio: aim for
:1 (lower is better for inflammation resolution) - Typical fish oil is ~18% EPA and ~12% DHA by weight (so 1 gram EPA requires ~5.5g fish oil)
Conditions Where EPA Is Central:
- Neuroinflammatory disorders: depression (especially with elevated CRP >3 mg/L), ADHD, autism spectrum
- Metabolic syndrome, type 2 diabetes, NAFLD (via hypothalamic anti-inflammatory effects)
- Autoimmune diseases (rheumatoid arthritis, lupus): EPA reduces neutrophil activation and autoantibody production
- Cardiovascular disease: EPA reduces endothelial dysfunction, platelet aggregation (via PGI3 > TxA3 shift)
- Chronic pain syndromes: EPA-derived resolvins reduce peripheral and central sensitization
Intervention Strategy:
- Diet first: 2-3 servings fatty fish/week (salmon, mackerel, sardines) provides ~1-2g EPA+DHA
- Supplementation: 1-3g EPA+DHA daily (emphasize EPA for inflammation, DHA for brain structure)
- Reduce omega-6 competition: minimize seed oils (linoleic acid), grain-fed meat
- Aspirin co-administration: low-dose aspirin (75-100mg) acetylates COX-2 → ATL (aspirin-triggered lipoxins) and ATRvs (aspirin-triggered resolvins), amplifying EPA's resolving effects (used clinically in cardiovascular patients)
Cellular Toxicity Data:
Unlike linoleic acid (omega-6), which shows dose-dependent cytotoxicity (reduces cellular metabolism to 20-40% of control at physiological concentrations), EPA maintains cellular metabolism at ~100% of control across tested concentrations. This suggests EPA is not only anti-inflammatory but metabolically neutral to protective at the mitochondrial level—critical for chronic supplementation safety.
¶ Key Facts
- 20-carbon omega-3 PUFA with 5 double bonds (20:5n-3), first double bond at carbon 3 from methyl end
- Human conversion of ALA → EPA is <10% efficient (requires delta-6 desaturase, rate-limiting enzyme often saturated by dietary omega-6)
- Typical fish oil capsule (1000mg): ~180mg EPA + ~120mg DHA (300mg total omega-3)
- Precursor for E-series resolvins (RvE1, RvE2, RvE3), which act via ChemR23, BLT1, and other GPCRs
- Produces 3-series prostaglandins (PGE3, PGI3) and 5-series leukotrienes (LTB5)—both 10-100× less inflammatory than AA-derived mediators
- Competes with arachidonic acid for COX-2 and 5-LOX active sites (competitive inhibition)
- cPNI dosing: 1g/day additional EPA+DHA beyond baseline formulations for hypothalamic neuroinflammation
- Omega-3 Index >8% associated with 30% reduction in all-cause mortality; <4% increases cardiovascular risk 10-fold
- EPA shows minimal cytotoxicity in metabolic assays (unlike linoleic acid, which is highly cytotoxic)
- Half-life in RBC membranes: ~120 days (takes 3-4 months to reach steady-state with supplementation)
- Best dietary sources: wild salmon (1.5g/100g), mackerel (2.5g/100g), sardines (2.0g/100g), anchovies, algae (vegan source)
- RvE1 potency: active at 10⁻¹² M concentrations (picomolar), making it one of the most potent endogenous anti-inflammatory mediators
- Aspirin doubles EPA's conversion to resolvins (aspirin-triggered resolvins = ATRvs)
¶ Connections
- Omega-3 fatty acids — EPA is one of the two primary long-chain marine omega-3s
- DHA — partner omega-3 in fish oil; DHA emphasizes brain structure, EPA emphasizes resolution
- arachidonic acid — direct enzymatic competitor; EPA displaces AA from membranes and competes for COX/LOX
- alpha-linolenic acid — plant omega-3 precursor; poorly converted to EPA in humans (5-10%)
- linoleic acid — omega-6 that competes for delta-6 desaturase and increases AA levels; EPA opposes this
- omega-6 to omega-3 ratio — EPA supplementation corrects modern mismatch (15:1 → target 3:1)
- resolvins — EPA is the exclusive precursor for E-series resolvins (RvE1, RvE2, RvE3)
- specialized pro-resolving mediators — EPA-derived SPMs actively terminate inflammation and promote healing
- COX-2 — metabolizes EPA to 3-series prostaglandins; aspirin-acetylated COX-2 produces 18R-HEPE
- 5-LOX — converts EPA to 5-series leukotrienes and contributes to resolvin biosynthesis
- PLA2 — phospholipase A2 releases EPA from membrane phospholipids for eicosanoid synthesis
- cell membrane — EPA incorporates into phospholipid bilayer sn-2 position, altering membrane fluidity
- membrane fluidity — EPA's five double bonds increase membrane flexibility and receptor mobility
- inflammation — EPA-derived mediators shift balance from pro-inflammatory (AA) to pro-resolving
- neuroinflammation — EPA specifically targets hypothalamic inflammation in cPNI protocols
- hypothalamic inflammation — 1g/day EPA+DHA reduces gliosis, restores leptin/insulin sensitivity
- NF-κB — EPA inhibits NF-κB nuclear translocation, reducing IL-6, TNF-α, COX-2 transcription
- PPAR signaling — EPA activates PPAR-α/γ, upregulating fatty acid oxidation and anti-inflammatory genes
- efferocytosis — RvE1 and RvE2 enhance macrophage phagocytosis of apoptotic cells (resolution)
- lipid mediator class switching — transition from AA-derived (inflammatory) to EPA-derived (resolving) mediators
- ChemR23 — GPCR for RvE1; triggers resolution signaling cascade
- Aspirin-triggered resolvins — low-dose aspirin acetylates COX-2, converting EPA to ATRvs with enhanced potency
- cytotoxicity — EPA shows minimal cellular toxicity unlike pro-inflammatory linoleic acid
- fatty fish — primary dietary source; wild-caught preferred for higher EPA content
- metabolic syndrome — EPA reduces insulin resistance via hypothalamic anti-inflammatory effects
- depression — EPA supplementation effective in depression with elevated CRP (>3 mg/L)
- endothelial dysfunction — EPA-derived PGI3 improves vasodilation, reduces platelet aggregation
- neutrophil — EPA reduces neutrophil chemotaxis (via LTB5 vs LTB4) and NETosis
¶ Module References
- Module 5